Caribou Biosciences, Inc. CRBU

CRBU Company Overview

Caribou Biosciences, Inc. is a clinical-stage biotechnology company focused on developing genome-edited cell therapies for oncology and autoimmune diseases. The company operates within the biotechnology and gene-editing industries and is best known for its work advancing CRISPR-based technologies for allogeneic, or off-the-shelf, cell therapies. Caribou’s primary revenue sources have historically included collaboration agreements, licensing arrangements, and research funding, while its long-term strategy centers on commercialization of proprietary therapeutic candidates. The company’s platform is built around CRISPR hybrid RNA-DNA guide technology, often referred to as chRDNA, which is designed to improve editing specificity and reduce off-target effects in engineered cell therapies.

Caribou Biosciences was founded in 2011 and traces its scientific origins to foundational CRISPR research conducted by scientists including Jennifer Doudna. The company evolved from an early-stage genome-editing platform business into a therapeutics-focused biotechnology company emphasizing immune cell engineering. Caribou completed its initial public offering in 2021 and has since concentrated on advancing a pipeline of CAR-T and CAR-NK therapeutic candidates. The company’s positioning within the cell therapy market is tied to its proprietary genome-editing capabilities, manufacturing approach for allogeneic therapies, and intellectual property portfolio associated with CRISPR technologies.